Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says

MT Newswires Live

May 27

The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian.

"For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation," Reuters quoted Tian as saying.

JW is "actively seeking cooperation" with companies outside China for assets in its pipeline, the report said, citing Tian.

Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.

Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2638054115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638054115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638054115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638054115","market":"nz","top_or_hot":-1,"title":"Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says","media":"MT Newswires Live","content":"<html><body><p> The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2126) CEO Leo Tian.</p><p>\"For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation,\" Reuters quoted Tian as saying.</p><p>JW is \"actively seeking cooperation\" with companies outside China for assets in its pipeline, the report said, citing Tian.</p><p>Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.</p><p>Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-27 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2126) CEO Leo Tian.</p><p>\"For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation,\" Reuters quoted Tian as saying.</p><p>JW is \"actively seeking cooperation\" with companies outside China for assets in its pipeline, the report said, citing Tian.</p><p>Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.</p><p>Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638054115","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638054115","pubTimestamp":1779874587,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW  Therapeutics  CEO Leo Tian.\"For us, everything is business as usual. Our cross-border collaborations, especially in CGT , are particularly dependent on international cooperation,\" Reuters quoted Tian as saying.JW is \"actively seeking cooperation\" with companies outside China for assets in its pipeline, the report said, citing Tian.Global pharmaceutical companies have been ramping up their search for Chinadeveloped experimental drugs in a bid to cut costs before their patents expire, Reuters said.Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK4539":"次新股","LENZ":"Therapeutics","02126":"药明巨诺-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK4139":"生物科技","BK4007":"制药"},"translate_title":"市场热议：JW Therapeutics首席执行官表示，尽管跨境科技交易受到审查，但中国制药商仍“一切如常”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"02126":1},"content_text":"The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian.\"For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly ⁠dependent on international cooperation,\" Reuters quoted Tian as saying.JW is \"actively seeking cooperation\" with companies outside China for assets in its pipeline, the report said, citing Tian.Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}